Some patients with a common type of stroke benefit from a clot-busting drug given between 4.5 and 24 hours after symptoms emerged, according to a new study.

TNKase is administered as a single intravenous bolus over 5 seconds. The Food and Drug Administration (FDA) has approved TNKase ® (tenecteplase) for the treatment of acute ischemic stroke (AIS) in ...

Bayer recently reported that its oral factor XIa inhibitor asundexian reduced the risk of recurrent ischemic stroke in patient ...

The PSD-95 inhibitor also had a favorable safety profile in phase III trial ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The study examined 352 individuals with stroke ...

Antidepressant therapy may independently improve recovery from dysphagia after acute ischemic stroke through multiple ...

DMT’s hallucinogenic properties could complicate its clinical use. However, because beneficial effects were observed at sub-psychedelic doses, this may be manageable. If the results translate to ...

Recent research has revealed compelling evidence supporting tenecteplase as a more effective treatment for ischemic strokes compared to traditional alteplase therapy. This discovery could mark a major ...

For acute ischemic stroke within 48 hours of onset, the novel sublingual combination of edaravone (Radicava) with dexborneol appeared to dramatically improve functional outcomes in the phase III TASTE ...

Share on Pinterest Adding blood thinners to clot-busting medication after a stroke does not appear to improve the outcomes, according to a new study. credit: szjphoto/Getty Images. About 15 million ...

A retrospective study shows a synergistic interaction between Parkinson disease and stroke, leading to increased long-term mortality risk.